系统性自身免疫性风湿病女性的性功能障碍:系统评价与Meta分析
该系统评价与Meta分析纳入68项研究、5457例诊断为系统性自身免疫性风湿病(SARD)的女性(平均年龄43.7[12.9]岁),估计总体性功能障碍(SD)患病率为63%(95%CI:56,69%,I²=94%),总体女性性功能指数(FSFI)总分为19.7分(95%CI:18.4,21,I²=97%);仅纳入性活跃女性时SD患病率为60%(95%CI:53,67%,I²=88%),FSFI总分为22分(95%CI:20.8,23.1,I²=93%)。干燥综合征和系统性硬化症女性的SD水平最高(分别为74%,95%CI:58,87%,I²=84%和69%,95%CI:54,83%,I²=94%)。作者认为SARD女性的性功能似乎严重受损,与SARD类型无关,SD的筛查和治疗应成为医疗临床实践不可或缺的一部分。
要点
- SARD女性总体SD患病率为63%(95%CI:56,69%,I²=94%),FSFI总分为19.7分(95%CI:18.4,21,I²=97%)。
- 仅性活跃女性中SD患病率为60%(95%CI:53,67%,I²=88%),FSFI总分为22分(95%CI:20.8,23.1,I²=93%)。
- 干燥综合征和系统性硬化症女性SD水平最高,分别为74%(95%CI:58,87%,I²=84%)和69%(95%CI:54,83%,I²=94%)。
核心结论
- SARD女性的性功能似乎严重受损,与SARD类型无关。
- 作者认为SD的筛查和治疗应成为女性SARD患者医疗临床实践不可或缺的一部分。
研究设计与样本
- 系统评价与Meta分析,纳入68项研究、5457例诊断为SARD的女性(平均年龄43.7[12.9]岁)。
- 检索PubMed、EMBASE和Cochrane对照试验中心注册库(CENTRAL)数据库及灰色文献,截至2022年2月。
- 采用Hoy风险偏倚工具评价所选记录质量,采用双反正弦变换的比例随机效应Meta分析,并进行亚组分析、敏感性分析及重要相关因素的Meta回归。
- 研究方案注册号:PROSPERO CRD42021287346。
主要发现
- 总体SD患病率为63%(95%CI:56,69%,I²=94%),总体FSFI总分为19.7分(95%CI:18.4,21,I²=97%)。
- 仅纳入性活跃女性时,SD患病率为60%(95%CI:53,67%,I²=88%),FSFI总分为22分(95%CI:20.8,23.1,I²=93%)。
- 干燥综合征女性SD水平最高,为74%(95%CI:58,87%,I²=84%)。
- 系统性硬化症女性SD水平为69%(95%CI:54,83%,I²=94%)。
关键数值与推荐
- 总体SD患病率63%(95%CI:56,69%,I²=94%)。
- 总体FSFI总分19.7分(95%CI:18.4,21,I²=97%)。
- 性活跃女性SD患病率60%(95%CI:53,67%,I²=88%)。
- 性活跃女性FSFI总分22分(95%CI:20.8,23.1,I²=93%)。
- 干燥综合征女性SD患病率74%(95%CI:58,87%,I²=84%),系统性硬化症女性SD患病率69%(95%CI:54,83%,I²=94%)。
临床怎么用
- 作者认为SD的筛查和治疗应成为女性SARD患者医疗临床实践不可或缺的一部分。
局限性
- 总体SD患病率分析异质性I²=94%。
- 总体FSFI总分分析异质性I²=97%。
- 性活跃女性SD患病率分析异质性I²=88%。
- 性活跃女性FSFI总分分析异质性I²=93%。
- 干燥综合征女性SD分析异质性I²=84%,系统性硬化症女性SD分析异质性I²=94%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In women with systemic autoimmune rheumatic diseases (SARDs), female sexual dysfunction (SD) remains underestimated. We aimed to explore the prevalence and correlates of SD in females with SARDs. METHODS: We performed a systematic review and meta-analysis of studies assessing the prevalence of SD and the pooled Female Sexual Function Index (FSFI) scores in this setting (PROSPERO: CRD42021287346). We searched PubMed, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) databases and grey literature until February 2022. We evaluated the quality of the selected records using the Hoy Risk of Bias tool. A random-effects meta-analysis of proportions with the double arcsine transformation was conducted. Subgroup and sensitivity analyses, as well as meta-regression of important correlates, were conducted. RESULTS: We included 68 studies with 5457 females diagnosed with a SARD (mean age: 43.7 [12.9] years). The overall SD prevalence was 63% (95% CI: 56, 69%, I2 = 94%) and the overall FSFI total score was 19.7 points (95% CI: 18.4, 21, I2 = 97%). Including only sexually active females, the SD prevalence was estimated as 60% (95% CI: 53, 67%, I2 = 88%), whereas the FSFI total score was 22 points (95% CI: 20.8, 23.1, I2 = 93%). Across the different SARDs, women with Sjögren's syndrome and systemic sclerosis reported the highest levels of SD (74%, 95% CI: 58, 87%, I2 = 84% and 69%, 95% CI: 54, 83%, I2 = 94%, respectively). CONCLUSION: Sexual function in females with SARDs seems to be severely impaired, irrespective of the type of SARD. Screening and treatment of SD in females with SARDs should become an integral part of healthcare clinical practice.
引用
- Minopoulou I, Pyrgidis N, Tishukov M, et al. Sexual dysfunction in women with systemic autoimmune rheumatic disorders: a systematic review and meta-analysis. Rheumatology (Oxford). 2023. PMID: 35951753. doi:10.1093/rheumatology/keac457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。